Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | KDM1A | O60341 | 8/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 2/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PDE9A | O76083 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19608729 | 0.98 | ALDH1A1 (0.50) | ALDH1A1CYP2A6KDM1APDE3BPDE3A | |
| SCHEMBL16945915 | 0.92 | KDM1A (0.45) | ALDH1A1CYP2A6KDM1APDE3BPDE3A | |
| SCHEMBL91862 | 0.90 | ALDH1A1 (0.53) | ALDH1A1CYP2A6KDM1APDE3BPDE3A | |
| SCHEMBL91992 | 0.90 | ALDH1A1 (0.53) | ALDH1A1CYP2A6KDM1APDE3BPDE3A | |
| SCHEMBL28428605 | 0.89 | ALDH1A1 (0.52) | ALDH1A1CYP2A6KDM1APDE3BPDE3A | |
| SCHEMBL16604329 | 0.87 | PDE3B (0.48) | ALDH1A1CYP2A6KDM1APDE3BPDE3A | |
| SCHEMBL16945886 | 0.85 | AR (0.48) | ALDH1A1CYP2A6KDM1APDE3BPDE3A | |
| SCHEMBL13967517 | 0.84 | PTGS2 (0.46) | KDM1APDE3BPDE3APTGS1 | |
| SCHEMBL13198901 | 0.84 | PTGS2 (0.41) | KDM1APDE3BPDE3APTGS1 | |
| SCHEMBL397141 | 0.83 | KIF11 (0.61) | PDE3BPDE3AKIF11CYP11B2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400172-A2 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | Incyte Holdings Corporation (US) | 2024-07-17 | — | — | EP | disclosed |
| EP-3715347-B1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE HOLDINGS CORP (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3715347-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | Incyte Holdings Corporation (US) | 2020-09-30 | — | — | EP | disclosed |
| CN-111362805-A | Method for synthesizing biphenyl compounds by taking phenol as raw material | 遵义医科大学 | 2020-07-03 | — | — | CN | disclosed |
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| US-20200181492-A1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DEVICE | MERCK PATENT GMBH (DE) | 2020-06-11 | — | — | US | disclosed |
| EP-3354652-B1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE HOLDINGS CORP (US) | 2020-05-06 | — | — | EP | disclosed |
| WO-2019179962-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019030150-A1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DEVICE | MERCK PATENT GMBH (DE) | 2019-02-14 | — | — | WO | disclosed |
| WO-2019030153-A1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DEVICE | MERCK PATENT GMBH (DE) | 2019-02-14 | — | — | WO | disclosed |
| US-20090267025-A1 | LIQUID CRYSTAL SYSTEM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2009-10-29 | — | — | US | disclosed |
| US-7531106-B2 | Mesogenic compounds, medium for electro-optical displays and electro-optical display | MERCK PATENT GMBH (DE) | 2009-05-12 | — | — | US | disclosed |
| US-7482044-B2 | Liquid crystalline medium and liquid crystal display | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2009-01-27 | — | — | US | disclosed |
| US-7445819-B2 | Liquid crystalline medium and liquid crystal display | MERCK PATENT GMBH (DE) | 2008-11-04 | — | — | US | disclosed |
| US-7440160-B2 | Electro-optical light modulating element, electro-optical display and modulating medium | MERCK PATENT GMBH (DE) | 2008-10-21 | — | — | US | disclosed |
| US-20080167482-A1 | mesogenic group is linked to the C-atom No. 5 of the 1,3-dioxane-5-yl group; media showing a blue phase and their use in electro-optical light modulation elements | MERCK PATENT GMBH (DE) | 2008-07-10 | — | — | US | disclosed |
| US-20080124492-A1 | Liquid crystalline medium and liquid crystal display | MERCK PATENT GMBH | 2008-05-29 | — | — | US | disclosed |
| US-20080116419-A1 | Mesogenic Compounds, Liquid Crystal Medium and Liquid Crystal Display | MERCK PATENT GMBH (DE) | 2008-05-22 | — | — | US | disclosed |
| EP-1116770-B1 | NEMATIC LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY USING THE SAME | DAINIPPON INK & CHEMICALS (JP) | 2008-04-02 | — | — | EP | disclosed |
| US-20070235688-A1 | Liquid crystalline medium and liquid crystal display | MERCK PATENT GESELLSCHAFT | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080116419-A1 | Mesogenic Compounds, Liquid Crystal Medium and Liquid Crystal Display | CRY1, CRY2, IK | ALDH1A1 2978/4885CYP2A6 2777/4885KDM1A 3592/4885 |
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | JAK1, JAK2, JAK3 | ALDH1A1 1457/4885CYP2A6 3258/4885KDM1A 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.